NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...

I am delighted that, following our recently closed $50 million Series D financing ... master switch that modulates inflammation, plays a key role in controlling obesity and obesity-associated ...

Johnson & Johnson's recent earnings beat expectations, with strong Medicine and MedTech growth. Read why I have a buy rating ...

Some even believe that the new GLP-1 drugs are playing a direct role ... relative to revenues in recent years. Since CapEx is a key component in calculating free cash flow, its increase has ...

I am delighted that, following our recently closed $50 million Series D financing, we have accelerated our ... an intracellular sensor and master switch that modulates inflammation, plays a key role ...

While GLP-1 receptor agonists like semaglutide help with weight loss, new research shows users often fall short on vital nutrients, spotlighting the urgent need for tailored dietary guidance.

Our study found a similar incidence of obesity-related cancer among patients treated with first-generation glucagon-like peptide-1 receptor agonists (GLP-1s) and with bariatric surgery over an ...

A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide ... Investors now face a key question: Should they favor the stability and proven track record of a pharmaceutical giant ...

Yankees outfielder Aaron Judge (99) hits a solo home run against the San Diego Padres. Robert Sabo for NY Post Access the Yankees beat like never before Don’t miss Greg Joyce’s text messages ...

Global launch potential from patent expiry is a key trigger The big trigger is the expiry of the Semaglutide patent—a key GLP-1 molecule ... has cleared the NISM-Series-XV: Research Analyst ...